Epidural Tap in Labor Analgesia FOR LABOR ANALGESIA

Sponsor
Medipol University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05499234
Collaborator
(none)
70
1
2
4
17.6

Study Details

Study Description

Brief Summary

The dural epidural tap method is performed by creating a dural perforation with a spinal needle placed through epidural needle, followed by placement of a catheter into the epidural space. No medications are administered through spinal needle. This prospective, randomized study includes 70 ASA II primigravid women with cervical dilatation between 4-6 cm and demanding epidural analgesia during spontaneous vaginal delivery.In the first group, 20 mL of 0.125% bupivacaine + 2 mcg/mL fentanyl solution and in the second group, 20 mL of 0.0625% bupivacaine + 2 mcg/mL fentanyl solution was administered as the first dose through the epidural catheter. Then, the visual analog scale (VAS) score was aimed to be below 4 in both groups.

Condition or Disease Intervention/Treatment Phase
Phase 1

Detailed Description

This prospective, randomized study includes 70 ASA II primigravid women with cervical dilatation between 4-6 cm and demanding epidural analgesia during spontaneous vaginal delivery. Participants with pregnancy-related diseases (such as gestational hypertension, gestational diabetes, preeclampsia) and contraindications for neuraxial block (infection, coagulation disorder, severe hypovolemia, sepsis, neurological deficit, cardiac valve stenosis or hypertrophic obstructive cardiomyopathy) will be excluded from the study. Women with fetal malpresentation and fetal anomaly will also be excluded.

Participants will randomly be divided into 2 equal groups. Immediately before epidural placement, subjects will be marked a VAS score during an active contraction. All subjects will have an intravenous catheter placed and be monitored with NST, noninvasive blood pressure and pulse oximetry.

The epidural space will be identified by a loss of resistance technique to saline. CSF flow will be observed at L3-L4 or L4-L5 level by puncturing the dura with a 27 G needle before inserting the epidural catheter. A combined spinal epidural set with 18 G Tuohy needle will be used in both groups. In the first group, 20 mL of 0.125% bupivacaine + 2 mcg/mL fentanyl solution and in the second group, 20 mL of 0.0625% bupivacaine + 2 mcg/mL fentanyl solution will be administered as the first dose through the epidural catheter. Then, the visual analog scale (VAS) score will be aimed to be below 4 in both groups. Patients with a VAS score of 4 or higher 15 minutes after the first dose received, an additional 10 mL dose of the same solution will be given. An additional 10 mL dose also will be administered when the VAS score is 4 or higher until crowning.

Before the epidural catheter placed; age, weight, height, blood pressure of the participants, gestational week, use of oxytocin during delivery, cervical dilatation amount before the procedure and fetal heart rate will be recorded. After each dose of administration, whether maternal hypotension, fetal bradycardia, pruritus, nausea-vomiting or motor block development will be monitored. The total amount of drug administered through the epidural catheter, the time between applications, and the number of bolus doses administered will also be recorded.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Intervention Model Description:
70 ASA II primigravid women with cervical dilatation between 4-6 cm and demanding epidural analgesia during spontaneous vaginal delivery70 ASA II primigravid women with cervical dilatation between 4-6 cm and demanding epidural analgesia during spontaneous vaginal delivery
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Masking Description:
Participants and the medical staff administrating epidural drugs will not be told about the concentration. Because volumes will be same, they would not predict which group.
Primary Purpose:
Supportive Care
Official Title:
Effects of Different Local Anesthetic Concentrations With Epidural Tap Method for Labor Analgesia
Actual Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Sep 15, 2022
Anticipated Study Completion Date :
Nov 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: High concentration

Epidural analgesia with 20 mL of 0.125% bupivacaine + 2 mcg/mL fentanyl solution

Drug: Dolantin
If VAS score is more than 4 even after additional dose, use dolantin 1 mg/kg
Other Names:
  • Meperidin
  • Drug: Paracetamol
    If VAS score is more than 4 even after dolantin 1 mg/kg, 10 mg/kg paracetamol IV
    Other Names:
  • Parol
  • Experimental: Low concentration

    Epidural analgesia with 20 mL of 0.0625% bupivacaine + 2 mcg/mL fentanyl solution

    Drug: Dolantin
    If VAS score is more than 4 even after additional dose, use dolantin 1 mg/kg
    Other Names:
  • Meperidin
  • Drug: Paracetamol
    If VAS score is more than 4 even after dolantin 1 mg/kg, 10 mg/kg paracetamol IV
    Other Names:
  • Parol
  • Outcome Measures

    Primary Outcome Measures

    1. Change the need of bupivacaine for epidural analgesia. [In an hour]

      primary aim of this study is to achieve VAS scores equal to or below 4 via different bupivacaine concentrations

    Secondary Outcome Measures

    1. Complication comparison [2 days]

      measure the number of treatment related complications and compare these measurements between the groups

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • ASA II primigravid women

    • with cervical dilatation between 4-6 cm, demanding epidural analgesia during spontaneous vaginal delivery

    Exclusion Criteria:
    • Participants with pregnancy-related diseases

    • gestational hypertension

    • gestational diabetes

    • preeclampsia/ celmpsia

    • contraindications for neuraxial block

    • infection

    • coagulation disorders

    • severe hypovolemia

    • sepsis

    • neurological deficit

    • cardiac valve stenosis or hypertrophic obstructive cardiomyopathy

    • Women with fetal malpresentation and fetal anomaly

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Istanbul Medipol University Istanbul Bağcılar Turkey 34700

    Sponsors and Collaborators

    • Medipol University

    Investigators

    • Principal Investigator: Pınar Uçar, Medipol University
    • Study Chair: Emine Uzunoğlu, Medipol University
    • Study Director: Pelin Karaaslan, Medipol University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Pelin Karaaslan, Associate Professor, Medipol University
    ClinicalTrials.gov Identifier:
    NCT05499234
    Other Study ID Numbers:
    • KARAASLANP
    First Posted:
    Aug 12, 2022
    Last Update Posted:
    Aug 12, 2022
    Last Verified:
    Aug 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Pelin Karaaslan, Associate Professor, Medipol University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 12, 2022